BRAF Inhibitors Reprogram Cancer-Associated Fibroblasts to Drive Matrix Remodeling and Therapeutic Escape in Melanoma

BRAF inhibitor induced BRAF-CRAF heterodimerization and subsequent activation of ERK signaling in cancer-associated fibroblasts, leading to inactivation of the β-catenin destruction complex.